Ethical considerations in CYP2D6 genotype testing for codeine-prescribed breastfeeding mothers

M. Kurtz, P. Black Golde, N. Berlinger

Research output: Contribution to journalComment/debatepeer-review

Abstract

In this issue, Madadi et al. report on interviews with codeine-prescribed breastfeeding mothers concerning preferences and attitudes toward receiving their CYP2D6 genotype and overall study findings. We address three sets of ethics questions raised by this article. Should genetic information be disclosed to research participants in genetic research? What should clinicians take into account when considering this genetic test in managing infant opioid toxicity risk? What conditions support or hinder the integration of genetic information into patient care?

Original languageEnglish (US)
Pages (from-to)760-762
Number of pages3
JournalClinical pharmacology and therapeutics
Volume88
Issue number6
DOIs
StatePublished - Dec 2010

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Ethical considerations in CYP2D6 genotype testing for codeine-prescribed breastfeeding mothers'. Together they form a unique fingerprint.

Cite this